[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BioTechVisions "💼 Brandon Capital Closes Historic A$439M Fund VI to Fuel Global Life Sciences Innovation 🚀 Big move in biotech venture capital Brandon Capital has just closed its biggest fund yetA$439 million (US $XXX million)surpassing its mid2024 first close of A$270M. Backed by Australias National Reconstruction Fund Corporation and a mix of institutional LPs Brandon is doubling down on life sciences innovation from Australia and New Zealand while accelerating its global expansion into the UK Europe and the U.S. Since 2007 the firm has now raised over A$1 billion across six funds and backed more than 60"
@BioTechVisions on X 2025-07-25 15:10:54 UTC XX followers, XX engagements

"🛑 Novartis Stops ianalumab in Hidradenitis Suppurativa But Eyes Autoimmune Boldly Novartis has pulled the plug on ianalumab for hidradenitis suppurativa after its Phase X trial failed to meet efficacy benchmarksdespite showing some promise vs placebo. 🧪 But its not the end for this dual-action B celldepleting antibody. ianalumab is still on track in Phase X trials for Sjgrens syndrome (data expected H2 2025) SLE and systemic sclerosis plus a program in immune thrombocytopenia. Meanwhile Novartis is pivoting its HS focus to remibrutinib its BTK inhibitor now heading into Phase X. Big"
@BioTechVisions on X 2025-07-17 15:08:17 UTC XX followers, XXX engagements

"🌟 BMS Taps AstraZeneca Veteran Cristian Massacesi as New CMO & Head of Development Big leadership shake-up at BMS Dr. Cristian Massacesi joins Bristol Myers Squibb as Executive VP Chief Medical Officer & Head of Development starting August X 2025. He will oversee all early and late-stage product development and sit on the exec leadership team. Massacesi brings a rich track recordfrom AstraZeneca and Alexionwhere he led global oncology R&D and oversaw over XXX clinical trials culminating in key regulatory approvals. He's widely respected for championing innovation in bispecific antibody"
@BioTechVisions on X 2025-07-25 15:07:49 UTC XX followers, XX engagements

"🚀 Dispatch Bio Raises $216M to Launch Solid Tumor CART Innovation with Carl June at Helm 🌟 Big leap forward in cancer therapy Dispatch Bio a brainchild of CART innovator Carl June M.D. has raised $XXX million to launch its first-in-class Flare platform aimed at universal solid tumor treatment. This platform introduces a novel antigen via viral vector to tag tumors and reprogram the microenvironmentenabling deep immune responses without harming healthy cells. With scientific roots from labs led by June Andy Minn Chris Garcia and Kole Roybal Dispatch is bridging advanced immunology and"
@BioTechVisions on X 2025-07-23 19:38:49 UTC XX followers, XX engagements

"🚀 AN Venture Partners Raises a Record $200M Biotech FundBetting Big on Japanese Science 💰 $200M inaugural fund anchored by Japan Investment Corporation Shionogi Otsuka MUFG & Sumitomo Mitsui 🌏 Tokyo + San Francisco team: building Japanese science into global biotech companies 🔬 Invests across all stagesfrom academic proof-of-concept to clinical readiness ⚡ Portfolio includes X startups with first investments starting in Dec 2023 (e.g. Capacity Bio Typewriter Therapeutics) 🎤 Hosts SciencetoStartup events and partners with AMED/government to strengthen Japan's biotech ecosystem This isnt"
@BioTechVisions on X 2025-07-02 17:19:50 UTC XX followers, XX engagements

"🛡 Arrowhead Stands Firm on $825M Sarepta Deal Amid Pharma Turbulence Arrowhead isnt backing down. Despite compliance issues and safety-related delays at Sarepta Arrowhead says it's on track to receive $300M in milestone payments by the end of the yearpart of a deal that could be worth up to $825M 💰. While Sareptas stock is down Arrowhead reassures stakeholders that Sarepta remains committedand if they fail to pay Arrowhead has recourse to reclaim the licensed IP. Still analysts warn that Arrowhead may need a third partner to fund these programs if Sarepta stumbles. This deal isnt just about"
@BioTechVisions on X 2025-07-23 19:37:01 UTC XX followers, XXX engagements